Stroke Trials Registry

Swedish Cooperative Study

Principal Investigator
M Britton

PI Address
Department of Medicine, Danderyd, Sweden.

Contact Address
C. Helmers, MD, Department of Medicine, Huddinge Hospital, Karolinska Institute, 141 86 Huddinge, Sweden.

Sponsor

Study Size Actual:	505
Centers Actual:	6
Max Time from onset:	21 Days

Status:
Trial complete. Results published 3/87.

Interventions:

Aspirin (stroke prevention)
Antiplatelet agent; inhibits thromboxane A2

Location(s):
Sweden

Year Published: 1987

Design:
Randomized, double-blind, placebo-controlled trial of 505 patients at 6 centers.

Inclusion Criteria
Cerebral infarction, minor or major stroke, preventing within 3 weeks of the event.

Exclusion Criteria
Atrial fibrillation in patients < 75 years old, myocardial infarction within previous 3 weeks; other needs for anticoagulants; receiving antiplatelet drugs; malignant or other serious disease influencing patient's immediate outcome; alcohol abuse or other anticipated reason for poor compliance; failure to give consent.

Patient Involvement:
Patients were randomized to receive treatment with acetylsalicylic acid (ASA) 1.5 g or placebo. Patients were examined by the clinical investigators at 1 and 3 months after entry and every 3 months thereafter for 2 years.

Primary Outcome:
Recurrent stroke or death.

Secondary Outcome:
Myocardial infarction and transient ischemic attack.

Results:
There was no significant difference between the ASA and placebo groups regarding either stroke recurrence or mortality.

Source of Information:
Stroke 1987 Mar-Apr;18(2):325-34.

Web Links and Publications:

High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study.
Stroke 1987 Mar-Apr;18(2):325-34.

This information last updated on: 3/7/2001

UID: 226